secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001104659-23-028031
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Novavax President of R&D Dr. Gregory Glenn to retire effective March 31, 2023
-----------------------------------------------------------------------------

- Dr. Gregory M. Glenn notified Novavax of his retirement as President, Research and Development.
- Retirement effective March 31, 2023; he will become Strategic Research & Development Advisor.
- No successor named in the filing; consulting services to follow retirement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000110465923028031/0001104659-23-028031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000110465923028031/tm238420d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-028031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer